While there may not be head-to-head trials between high-dose trivalent and standard-dose quadrivalent influenza vaccines, the high-dose is still the better option for adults aged 65 and older.
A unique study from the University of British Columbia (UBC) adds more evidence that pharmacist intervention can have a positive impact on cardiovascular risks. The second phase of the study began this fall.